P erhaps one of the most underestimated barriers to the effective personalization of medicine is the dearth of mechanism-specific therapies available for most human disorders. 1 The majority of current drugs act far downstream of the primary disease etiology and have been tested only in heterogeneous cohorts that aggregate multiple etiologies. As a result, with any projected improvement in diagnostic granularity or in the prediction of therapeutic responses, the pharmaceutical industry is faced with the prospect of fewer patients eligible for a given intervention, and physicians are faced with recommending therapies that they know may result in limited benefit in many patients. These closely aligned incentives have led to a tight coupling between the stratification of disease syndromes and the development of new therapies. This coupling, combined with the duration and expense of traditional drug discovery, has slowed the implementation of molecular medicine. The past decade has seen the emergence of academic drug discovery efforts, but limited resources or experience in core areas such as medicinal chemistry and regulatory science have hindered many such programs. Recently, rare orphan diseases have been seen as an effective entry way for new drugs into common syndromes, lowering the barriers to progress, but it remains clear that the broad implementation of precision medicine will require mechanism-focused diagnostics, disease modeling, and drug discovery on a new scale. 
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Finding New Ways to Find New Drugs
Finding new drugs is not easy. Finding new drugs quickly and at low cost is extremely hard. The conventional drug discovery and development sequence remains the backbone of most industrial programs. A specific target molecule is isolated; a robust and scalable assay for this single target's activity is designed and used to undertake unbiased screens of large chemical libraries for molecules with the desired effects on the target in this somewhat contrived context. 2 Subsequently the tools of medicinal chemistry are exploited to optimize efficacy and toxicity, testing in preclinical animal models is completed, and the drug ultimately advances to human studies. This paradigm has come under intense scrutiny in the past few years largely because of the time to clinic, the cost, and a consistent late-stage failure rate attributable to the lack of efficacy or to serious toxicity. However, there are no alternative approaches with consistent records of success. How can the process be accelerated?
Clearly, the choice of target is a major decision node in drug discovery and is often the source of subsequent problems. 3 Target choice is usually based on a host of factors that often have little to do with human disease biology. Among these factors are previous academic work in the area (rarely conditioned on therapeutic potential), the perceived ability of the target to be drugged, previously successful drugs in the same field, or data from animal models often with tenuous mechanistic links with the cognate human disease. Rarely is the target chosen because it is known to be a specific cause or proximate effector of the underlying disease. Often the target will have been studied intensively in one particular biological setting, but little may be known of its function in other cell types or tissues, or its behavior in the context of commonly encountered stressors or environmental factors including other drugs. Many preclinical animal models are expensive or are highly inbred, so it is not uncommon for drugs to reach the market after testing in only a few hundred genotypes. Thus, it is not surprising to find that many drugs suffer from unanticipated on-target effects in vivo, or apparently "idiosyncratic" reactions in the face of rare genetic variants.
3-5 Understanding such complexity requires systems level solutions. 6 
Complementary Approaches to Drug Discovery
An ideal drug discovery model would recapitulate all the relevant targets in a totally native context from the primary etiologic stimulus through to the terminal disease phenotype. This would allow the design of rational interventions during the earliest stages of disease and empiric balancing of efficacy against toxicity. This causal chain is best recapitulated in genetic disease models, but the costs of screening drugs in genetically modified models such as the mouse prohibit their use until late-stage development. More tractable in vivo models such as yeast, Caenorhabditis elegans, Drosophila, and zebrafish have proven promising, but there is still no clear integrated path from initial unbiased screening in these lower organisms to the clinic largely as a result of the added burden of target identification. 7, 8 Importantly, while there is a current regulatory mandate for a single target, phenotype-driven screening recognizes that many of the most effective drugs have multiple targets.
Need for Translational Phenotypes
As scientists search for innovative approaches to accelerate the translation from mechanistic discoveries to new drug entities, 
Putting It All Together
The elegant work described in the article by Gibson et al 9 in this issue of Circulation illustrates some of the strategies and experimental tools that might allow drug discovery and translational science to bridge the current gaps. Anchoring their approach in the human genetic evidence that cerebral cavernous malformations (CCMs) are caused by loss of function mutations in the gene CCM2, the authors built a system to allow them to screen thousands of drugs for their ability to rescue this rare anatomic disorder, which many would have considered "undruggable". In their first-round assay, the authors used small interfering RNAs to knock down CCM2 in an endothelial cell line. Recognizing that a priori assumptions on the cell biology of the disease might be skewed, they instead relied on automated imaging and subsequent machine learning. 10, 11 This allowed them to identify, in a relatively unbiased manner, the effects on endothelial cells of CCM2 loss of function in comparison with those of scrambled control small interfering RNAs. Once they had established an automated system capable of discriminating CCM2 cells from controls, they then tested 2100 annotated compounds not for their ability to inhibit a specific target, but rather for the capacity to rescue the complex multidimensional automated CCM2 cellular phenotype. For the next round of selection, they studied these first-round hits in a transcellular resistance assay measuring the ability of the endothelial cells to form a stable monolayer. Importantly, the investigators compared the top 38 compounds in this approach with the top 38 scored by 2 independent human observers. Of the 38 compounds identified by human observers, only one had an effect in the second-round assay, but 7 of the machine-identified compounds exhibited full or partial rescue in these same assays. The authors went on to study these drugs for their acute effects on an orthogonal assay: modifying subcutaneous wheals in an inducible CCM2 endothelial cell knockout mouse model, reasoning from previous work that this might reflect the biology of CCM2. Two compounds, tempol and cholecalciferol, which survived this screen, were then chosen for chronic testing in the CCM2 knockout mouse where both reduced the incidence of MRIdetected CCMs. Together these innovative staged experiments identified the acute effects of cholecalciferol and tempol on endothelial stability in CCM2 deficient cells and set the stage for further studies in human CCM2 disease.
Lessons Learned
There are numerous lessons to be taken from these experiments. By funneling the original library of 2100 compounds through progressively lower-throughput, but higher-resolution assays, the authors were able to efficiently restrict their in vivo experiments to a limited number of candidates. 2, 9 Although this example may represent a fortunate outcome, screens in other systems where complex native context is conserved suggest that modest numbers of drugs need be screened to identify primary hits, presumably because of the number of targets available and the bias toward drug like activity in current bioactive collections. 12 One might imagine, given the safety data available on cholecalciferol, that the regulatory progress of this repurposed compound is unlikely to be impeded by the absence of a specific target, but, for less well-annotated small molecules, there would now be a need for target identification before translation could be considered. Importantly, the in vivo results validate the automated phenotypes and directly infer that subjective phenotyping leads to substantial loss of information content. Perhaps the most generalizable lessons are that automated approaches to phenotype acquisition or phenotype analysis can offer powerful and scalable biological insights to match those of genomics, and that rigorous genetic anchoring combined with quantitative screenable phenotypes can dramatically accelerate translation.
The derivation of a phenotypic lexicon applicable from cellular or model organism systems biology all the way to the clinic will not solve every problem in modern drug discovery, but it will offer insights complementary to traditional approaches. A common phenotypic language around which to deconvolute the genome will enable integrated approaches where discovery, translational, and clinical science can inform each other in real time. The prospect of such integration might spur creative reinvention of the interfaces between academic and industrial activity in therapeutic discovery, not to mention reorientation of the regulatory environment around disease as the "target". It remains to be seen whether such cross-talk can transform the personalization of medicine, but, if machines can capture some of the intuition on which phenotyping has depended for so long, we may all benefit.
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